| scholarly article | Q13442814 |
| P50 | author | Karen Basen-Engquist | Q59770682 |
| Keiichi Fujiwara | Q92525856 | ||
| P2093 | author name string | David M O'Malley | |
| Raheela Ashfaq | |||
| Helen Huang | |||
| John K Chan | |||
| Mark F Brady | |||
| Robert S Mannel | |||
| Susan A Davidson | |||
| Deborah K Armstrong | |||
| Joan L Walker | |||
| Robert L Coleman | |||
| Krishnansu S Tewari | |||
| Stephen C Rubin | |||
| Thomas J Herzog | |||
| Byoung-Gie Kim | |||
| Paul Sabbatini | |||
| Nick M Spirtos | |||
| Paul DiSilvestro | |||
| P2860 | cites work | Reliability and validity of the functional assessment of cancer therapy-ovarian. | Q51068823 |
| Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. | Q52873404 | ||
| Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. | Q53093977 | ||
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. | Q53227029 | ||
| Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. | Q53376132 | ||
| Use of tumour markers in monitoring the course of ovarian cancer | Q57618550 | ||
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial | Q83287534 | ||
| Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm | Q83733281 | ||
| State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer | Q85579065 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial | Q88123697 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Incorporation of pazopanib in maintenance therapy of ovarian cancer | Q33417673 | ||
| Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial | Q33427744 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. | Q34520190 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study | Q37130150 | ||
| Latest research and treatment of advanced-stage epithelial ovarian cancer | Q37206348 | ||
| Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds | Q37643331 | ||
| Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? | Q38103775 | ||
| Emerging therapies: angiogenesis inhibitors for ovarian cancer | Q38497958 | ||
| Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study | Q40247128 | ||
| Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas | Q40428001 | ||
| Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. | Q40922743 | ||
| Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature | Q41211892 | ||
| Changing frequency of interim analysis in sequential monitoring | Q41223460 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse | Q46082130 | ||
| Whole-genome characterization of chemoresistant ovarian cancer | Q50272478 | ||
| P433 | issue | 6 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| ovarian cancer | Q172341 | ||
| bevacizumab | Q413299 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 779-791 | |
| P577 | publication date | 2017-04-21 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial | |
| P478 | volume | 18 |
| Q100385888 | A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer |
| Q53336368 | A new standard of care or just another option for patients with relapsed ovarian cancer? |
| Q92593158 | A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer |
| Q53823792 | A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. |
| Q64124105 | A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254) |
| Q90763649 | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q91613925 | A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer |
| Q60931043 | Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| Q94587270 | Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis |
| Q64231208 | Asian Society of Gynecologic Oncology International Workshop 2018 |
| Q90630067 | Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial |
| Q64085272 | Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies |
| Q92035335 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial |
| Q38641871 | Bevacizumab in advanced lung cancer: state of the art. |
| Q50664932 | Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. |
| Q41660578 | Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer |
| Q41524271 | Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? |
| Q55366217 | Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. |
| Q64119722 | Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients |
| Q99624566 | Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer |
| Q47796770 | Clinical trials in gynecologic oncology: Past, present, and future |
| Q89615461 | Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial |
| Q93215841 | Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer |
| Q92485539 | Effects of 12-Week Supplementation of a Polyherbal Formulation in Old Adults with Prehypertension/Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial |
| Q92610003 | Epithelial ovarian cancer |
| Q92642746 | Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK |
| Q61452291 | Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer |
| Q57174233 | Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives |
| Q90173973 | Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State |
| Q91813260 | In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening |
| Q58110912 | International Gynecologic Cancer Society (IGCS) 2018: Meeting report |
| Q92847051 | Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy |
| Q54952356 | Major clinical research advances in gynecologic cancer in 2017. |
| Q64112090 | Major clinical research advances in gynecologic cancer in 2018 |
| Q50209212 | Management of the toxicities of common targeted therapeutics for gynecologic cancers |
| Q89184189 | Metastatic gynecologic malignancies: advances in treatment and management |
| Q92847080 | New strategies in ovarian cancer treatment |
| Q93043588 | Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial |
| Q64118673 | Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma |
| Q47549019 | Optimizing treatment in recurrent epithelial ovarian cancer |
| Q92510493 | Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice |
| Q47306372 | Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial |
| Q90029904 | Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials |
| Q96353733 | Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer |
| Q90449579 | Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q98195717 | Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment |
| Q92726174 | Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer |
| Q91592033 | Phase III trials in ovarian cancer: The evolving landscape of front line therapy |
| Q89817054 | Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer |
| Q101143290 | Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer |
| Q55493644 | Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. |
| Q91971077 | Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer |
| Q91275584 | Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study |
| Q92487329 | Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study |
| Q98226191 | Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience |
| Q58610301 | Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) |
| Q89908227 | Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases |
| Q58729601 | Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials |
| Q94487374 | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial |
| Q46270437 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q90857957 | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer |
| Q55041688 | Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. |
| Q47685928 | Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients |
| Q92397942 | Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q58789499 | Targeting the Microenvironment in High Grade Serous Ovarian Cancer |
| Q49797241 | The NCI-MATCH trial and precision medicine in gynecologic cancers |
| Q49352712 | The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities |
| Q50129142 | The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis |
| Q52645823 | The role of tumor microenvironment in resistance to anti-angiogenic therapy. |
| Q49645276 | The roles of pathology in targeted therapy of women with gynecologic cancers |
| Q92847059 | Treatment of recurrent epithelial ovarian cancer |
| Q90122167 | Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
| Q47903356 | Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice |
| Q57175998 | Using PARP Inhibitors in Advanced Ovarian Cancer |
| Q90431245 | Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer? |
Search more.